GT Biopharma, Inc. (GTBP)
USD 2.3
(-1.29%)
USD 2.3
(-1.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.02 Million USD | 81.43% |
| 2022 | -5.49 Million USD | 38.48% |
| 2021 | -8.93 Million USD | -142.48% |
| 2020 | 21.03 Million USD | 57.82% |
| 2019 | 13.33 Million USD | 24.07% |
| 2018 | 10.74 Million USD | 2071.38% |
| 2017 | -545 Thousand USD | -104.4% |
| 2016 | 12.39 Million USD | 27.77% |
| 2015 | 9.7 Million USD | 287.38% |
| 2014 | 2.5 Million USD | -1.61% |
| 2013 | 2.54 Million USD | 44.85% |
| 2012 | 1.75 Million USD | -10.77% |
| 2011 | 1.96 Million USD | -6.68% |
| 2010 | 2.11 Million USD | 153.61% |
| 2009 | 832 Thousand USD | -60.87% |
| 2008 | 2.12 Million USD | 286.49% |
| 2007 | -1.14 Million USD | -157.69% |
| 2006 | 1.97 Million USD | -19.22% |
| 2005 | 2.44 Million USD | 173.52% |
| 2004 | -3.32 Million USD | -1469.34% |
| 2003 | -212 Thousand USD | 19.7% |
| 2002 | -264 Thousand USD | -900.0% |
| 2001 | 33 Thousand USD | 102.0% |
| 2000 | -1.65 Million USD | -1016.67% |
| 1999 | 180 Thousand USD | 190.0% |
| 1998 | -200 Thousand USD | -111.11% |
| 1997 | 1.8 Million USD | 100.0% |
| 1996 | 900 Thousand USD | -64.0% |
| 1995 | 2.5 Million USD | 1150.0% |
| 1994 | 200 Thousand USD | 125.0% |
| 1993 | -800 Thousand USD | -166.67% |
| 1992 | -300 Thousand USD | 0.0% |
| 1991 | -300 Thousand USD | 93.62% |
| 1990 | -4.7 Million USD | -30.56% |
| 1989 | -3.6 Million USD | -38.46% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.67 Million USD | -381.72% |
| 2024 Q1 | -1.92 Million USD | -88.05% |
| 2023 Q4 | -1.02 Million USD | 60.05% |
| 2023 Q2 | -2.64 Million USD | -39.46% |
| 2023 Q1 | -1.89 Million USD | 65.48% |
| 2023 Q3 | -2.55 Million USD | 3.44% |
| 2023 FY | -1.02 Million USD | 81.43% |
| 2022 Q1 | -7.03 Million USD | 21.24% |
| 2022 Q3 | -2.26 Million USD | 55.85% |
| 2022 Q2 | -5.13 Million USD | 27.05% |
| 2022 Q4 | -5.49 Million USD | -142.52% |
| 2022 FY | -5.49 Million USD | 38.48% |
| 2021 Q4 | -8.93 Million USD | 7.4% |
| 2021 FY | -8.93 Million USD | -142.48% |
| 2021 Q2 | -39.47 Million USD | -43.42% |
| 2021 Q1 | -27.52 Million USD | -230.84% |
| 2021 Q3 | -9.65 Million USD | 75.55% |
| 2020 Q2 | 21.11 Million USD | 57.71% |
| 2020 Q1 | 13.38 Million USD | 0.44% |
| 2020 Q3 | 22.76 Million USD | 7.81% |
| 2020 Q4 | 21.03 Million USD | -7.58% |
| 2020 FY | 21.03 Million USD | 57.82% |
| 2019 Q4 | 13.33 Million USD | 2.58% |
| 2019 Q1 | 11.43 Million USD | 6.46% |
| 2019 FY | 13.33 Million USD | 24.07% |
| 2019 Q2 | 12.08 Million USD | 5.65% |
| 2019 Q3 | 12.99 Million USD | 7.54% |
| 2018 Q4 | 10.74 Million USD | 14.35% |
| 2018 Q3 | 9.39 Million USD | 62.25% |
| 2018 Q2 | 5.79 Million USD | 6126.88% |
| 2018 Q1 | 93 Thousand USD | 117.06% |
| 2018 FY | 10.74 Million USD | 2071.38% |
| 2017 FY | -545 Thousand USD | -104.4% |
| 2017 Q1 | 11.55 Million USD | -6.75% |
| 2017 Q3 | -2.7 Million USD | -121.82% |
| 2017 Q2 | 12.38 Million USD | 7.12% |
| 2017 Q4 | -545 Thousand USD | 79.82% |
| 2016 FY | 12.39 Million USD | 27.77% |
| 2016 Q3 | 11.13 Million USD | 8.7% |
| 2016 Q2 | 10.24 Million USD | -2.87% |
| 2016 Q1 | 10.54 Million USD | 8.75% |
| 2016 Q4 | 12.39 Million USD | 11.29% |
| 2015 Q4 | 9.7 Million USD | 60.17% |
| 2015 FY | 9.7 Million USD | 287.38% |
| 2015 Q1 | 2.34 Million USD | -6.55% |
| 2015 Q2 | 4.27 Million USD | 82.78% |
| 2015 Q3 | 6.05 Million USD | 41.59% |
| 2014 Q2 | 2.82 Million USD | 3.75% |
| 2014 Q1 | 2.72 Million USD | 6.92% |
| 2014 Q4 | 2.5 Million USD | 6.64% |
| 2014 Q3 | 2.34 Million USD | -16.83% |
| 2014 FY | 2.5 Million USD | -1.61% |
| 2013 Q3 | 2.27 Million USD | 5.29% |
| 2013 Q1 | 1.92 Million USD | 9.56% |
| 2013 Q2 | 2.15 Million USD | 12.0% |
| 2013 Q4 | 2.54 Million USD | 12.11% |
| 2013 FY | 2.54 Million USD | 44.85% |
| 2012 Q3 | 2.61 Million USD | 19.05% |
| 2012 Q4 | 1.75 Million USD | -32.91% |
| 2012 FY | 1.75 Million USD | -10.77% |
| 2012 Q1 | 2.08 Million USD | 5.64% |
| 2012 Q2 | 2.2 Million USD | 5.77% |
| 2011 FY | 1.96 Million USD | -6.68% |
| 2011 Q1 | 2.03 Million USD | -3.46% |
| 2011 Q2 | 2 Million USD | -1.57% |
| 2011 Q3 | 198 Thousand USD | -90.12% |
| 2011 Q4 | 1.96 Million USD | 894.44% |
| 2010 FY | 2.11 Million USD | 153.61% |
| 2010 Q4 | 2.11 Million USD | 5.92% |
| 2010 Q3 | 1.99 Million USD | 12.86% |
| 2010 Q2 | 1.76 Million USD | 0.17% |
| 2010 Q1 | 1.76 Million USD | 111.78% |
| 2009 Q1 | 2.15 Million USD | 1.51% |
| 2009 FY | 832 Thousand USD | -60.87% |
| 2009 Q4 | 832 Thousand USD | -63.73% |
| 2009 Q3 | 2.29 Million USD | 6.65% |
| 2009 Q2 | 2.15 Million USD | -0.32% |
| 2008 Q1 | -102 Thousand USD | 91.05% |
| 2008 FY | 2.12 Million USD | 286.49% |
| 2008 Q4 | 2.12 Million USD | 0.66% |
| 2008 Q3 | 2.11 Million USD | 150.83% |
| 2008 Q2 | 842 Thousand USD | 925.49% |
| 2007 Q1 | -903 Thousand USD | -145.7% |
| 2007 FY | -1.14 Million USD | -157.69% |
| 2007 Q3 | -963 Thousand USD | -28.4% |
| 2007 Q2 | -750 Thousand USD | 16.94% |
| 2007 Q4 | -1.14 Million USD | -18.38% |
| 2006 Q4 | 1.97 Million USD | -31.1% |
| 2006 FY | 1.97 Million USD | -19.22% |
| 2006 Q2 | 3.19 Million USD | 8.77% |
| 2006 Q1 | 2.94 Million USD | 20.24% |
| 2006 Q3 | 2.86 Million USD | -10.35% |
| 2005 FY | 2.44 Million USD | 173.52% |
| 2005 Q4 | 2.44 Million USD | 163.62% |
| 2005 Q1 | -4.82 Million USD | -44.91% |
| 2005 Q2 | -4.45 Million USD | 7.65% |
| 2005 Q3 | -3.84 Million USD | 13.63% |
| 2004 Q3 | 978 Thousand USD | 93.28% |
| 2004 FY | -3.32 Million USD | -1469.34% |
| 2004 Q1 | -29 Thousand USD | 86.32% |
| 2004 Q4 | -3.32 Million USD | -440.18% |
| 2004 Q2 | 506 Thousand USD | 1844.83% |
| 2003 Q2 | -12 Thousand USD | 94.31% |
| 2003 Q1 | -211 Thousand USD | 20.08% |
| 2003 FY | -212 Thousand USD | 19.7% |
| 2003 Q3 | -78 Thousand USD | -550.0% |
| 2003 Q4 | -212 Thousand USD | -171.79% |
| 2002 Q1 | -982 Thousand USD | -3075.76% |
| 2002 FY | -264 Thousand USD | -900.0% |
| 2002 Q4 | -264 Thousand USD | 17.5% |
| 2002 Q3 | -320 Thousand USD | 57.5% |
| 2002 Q2 | -753 Thousand USD | 23.32% |
| 2001 Q1 | -639 Thousand USD | 61.27% |
| 2001 FY | 33 Thousand USD | 102.0% |
| 2001 Q4 | 33 Thousand USD | 26.92% |
| 2001 Q3 | 26 Thousand USD | 336.36% |
| 2001 Q2 | -11 Thousand USD | 98.28% |
| 2000 Q3 | -2.5 Million USD | 35.1% |
| 2000 Q4 | -1.65 Million USD | 34.05% |
| 2000 Q2 | -3.85 Million USD | -10.94% |
| 2000 FY | -1.65 Million USD | -1016.67% |
| 2000 Q1 | -3.47 Million USD | -2030.56% |
| 1999 Q3 | 700 Thousand USD | 800.0% |
| 1999 Q2 | -100 Thousand USD | 80.0% |
| 1999 Q1 | -500 Thousand USD | -150.0% |
| 1999 Q4 | 180 Thousand USD | -74.29% |
| 1999 FY | 180 Thousand USD | 190.0% |
| 1998 Q4 | -200 Thousand USD | 88.24% |
| 1998 FY | -200 Thousand USD | -111.11% |
| 1998 Q3 | -1.7 Million USD | -183.33% |
| 1998 Q1 | 2.8 Million USD | 55.56% |
| 1998 Q2 | -600 Thousand USD | -121.43% |
| 1997 Q4 | 1.8 Million USD | 212.5% |
| 1997 Q3 | -1.6 Million USD | 46.67% |
| 1997 Q2 | -3 Million USD | -350.0% |
| 1997 Q1 | 1.2 Million USD | 33.33% |
| 1997 FY | 1.8 Million USD | 100.0% |
| 1996 FY | 900 Thousand USD | -64.0% |
| 1996 Q2 | -600 Thousand USD | -126.09% |
| 1996 Q4 | 900 Thousand USD | 200.0% |
| 1996 Q3 | 300 Thousand USD | 150.0% |
| 1996 Q1 | 2.3 Million USD | -8.0% |
| 1995 Q1 | 1 Million USD | 400.0% |
| 1995 FY | 2.5 Million USD | 1150.0% |
| 1995 Q3 | 1.1 Million USD | -8.33% |
| 1995 Q4 | 2.5 Million USD | 127.27% |
| 1995 Q2 | 1.2 Million USD | 20.0% |
| 1994 FY | 200 Thousand USD | 125.0% |
| 1994 Q2 | -1.1 Million USD | 8.33% |
| 1994 Q1 | -1.2 Million USD | -50.0% |
| 1994 Q4 | 200 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | 118.18% |
| 1993 Q4 | -800 Thousand USD | -14.29% |
| 1993 FY | -800 Thousand USD | -166.67% |
| 1993 Q2 | -900 Thousand USD | -200.0% |
| 1993 Q1 | -300 Thousand USD | 0.0% |
| 1993 Q3 | -700 Thousand USD | 22.22% |
| 1992 Q4 | -300 Thousand USD | -200.0% |
| 1992 Q2 | -200 Thousand USD | 33.33% |
| 1992 Q1 | -300 Thousand USD | 0.0% |
| 1992 FY | -300 Thousand USD | 0.0% |
| 1992 Q3 | -100 Thousand USD | 50.0% |
| 1991 Q3 | -100 Thousand USD | 80.0% |
| 1991 Q2 | -500 Thousand USD | -66.67% |
| 1991 Q1 | -300 Thousand USD | 93.62% |
| 1991 Q4 | -300 Thousand USD | -200.0% |
| 1991 FY | -300 Thousand USD | 93.62% |
| 1990 Q4 | -4.7 Million USD | -1075.0% |
| 1990 Q3 | -400 Thousand USD | 0.0% |
| 1990 Q2 | -400 Thousand USD | -33.33% |
| 1990 Q1 | -300 Thousand USD | 91.67% |
| 1990 FY | -4.7 Million USD | -30.56% |
| 1989 Q2 | -400 Thousand USD | 0.0% |
| 1989 Q4 | -3.6 Million USD | -620.0% |
| 1989 Q3 | -500 Thousand USD | -25.0% |
| 1989 FY | -3.6 Million USD | -38.46% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 98.175% |
| Alkermes plc | -166.73 Million USD | 99.388% |
| Agenus Inc. | 274.13 Million USD | 100.372% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.055% |
| Aptorum Group Limited | 1.35 Million USD | 175.237% |
| Ardelyx, Inc. | 34.51 Million USD | 102.958% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 123.855% |
| Bicycle Therapeutics plc | -481.46 Million USD | 99.788% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 102.823% |
| ChromaDex Corporation | -24.04 Million USD | 95.754% |
| Chimerix, Inc. | -25.51 Million USD | 95.999% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 114.653% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 95.688% |
| CRISPR Therapeutics AG | -150.84 Million USD | 99.323% |
| Precision BioSciences, Inc. | -85.41 Million USD | 98.805% |
| Dyadic International, Inc. | -6.37 Million USD | 83.992% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 93.592% |
| Fortress Biotech, Inc. | 7.66 Million USD | 113.32% |
| Lantern Pharma Inc. | -21.7 Million USD | 95.296% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 99.076% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 88.049% |
| Incyte Corporation | -3.17 Billion USD | 99.968% |
| IO Biotech, Inc. | -140.69 Million USD | 99.274% |
| Jaguar Health, Inc. | 29.39 Million USD | 103.474% |
| Novavax, Inc. | -298.29 Million USD | 99.658% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 119.131% |
| Opthea Limited | 28.15 Million USD | 103.626% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 93.919% |
| ContextLogic Inc. | -232 Million USD | 99.56% |
| MiMedx Group, Inc. | -33.9 Million USD | 96.988% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 110.015% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 55.935% |
| NextCure, Inc. | -6.47 Million USD | 84.237% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 97.978% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 83.994% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 108.394% |
| Vaxcyte, Inc. | -368.22 Million USD | 99.723% |
| PDS Biotechnology Corporation | -32.7 Million USD | 96.879% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 105.909% |
| Pharming Group N.V. | 109.8 Million USD | 100.93% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 94.131% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 99.417% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 94.487% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 94.487% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 85.62% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 82.577% |
| Acelyrin, Inc. | -216.9 Million USD | 99.529% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 81.801% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 40.777% |
| Summit Therapeutics Inc. | 34.67 Million USD | 102.945% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 84.992% |
| Senti Biosciences, Inc. | 1.74 Million USD | 158.678% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 99.447% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 98.682% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 83.157% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 1123.364% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 262.58% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 99.128% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 99.393% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 100.921% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 86.559% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 99.209% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 114.809% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 99.579% |
| Immix Biopharma, Inc. | -17.5 Million USD | 94.169% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 99.678% |
| MEI Pharma, Inc. | -3.7 Million USD | 72.443% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 108.161% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 100.631% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 103.674% |
| Fortress Biotech, Inc. | 7.66 Million USD | 113.32% |
| Precigen, Inc. | -481 Thousand USD | -112.266% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 107.251% |
| AlloVir, Inc. | -62.69 Million USD | 98.371% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 98.164% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 101.656% |
| ImmuCell Corporation | 10.99 Million USD | 109.29% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 99.338% |
| Onconetix, Inc. | 5.33 Million USD | 119.151% |
| PureTech Health plc | -167.19 Million USD | 99.389% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 96.648% |
| Elevation Oncology, Inc. | -19.11 Million USD | 94.659% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 79.201% |
| Seer, Inc. | -4.24 Million USD | 75.92% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 95.752% |
| Innoviva, Inc. | 255.56 Million USD | 100.4% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 98.172% |
| ESSA Pharma Inc. | -33.62 Million USD | 96.963% |
| GlycoMimetics, Inc. | -40.98 Million USD | 97.509% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 98.494% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 101.667% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 99.239% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 92.631% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 96.464% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -1255.298% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 96.692% |
| Aptose Biosciences Inc. | -8.19 Million USD | 87.541% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 67.37% |
| Soligenix, Inc. | -4.95 Million USD | 79.38% |
| Century Therapeutics, Inc. | 847 Thousand USD | 220.543% |
| Kura Oncology, Inc. | -20.11 Million USD | 94.925% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 97.505% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 87.842% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 156.047% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 68.064% |
| Autolus Therapeutics plc | -186.59 Million USD | 99.453% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 97.929% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 99.63% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 102.979% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 100.621% |
| GRI Bio, Inc. | -1.79 Million USD | 43.088% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 88.634% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 96.93% |
| IGM Biosciences, Inc. | -72.6 Million USD | 98.594% |
| INmune Bio, Inc. | -25.41 Million USD | 95.982% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 100.676% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 97.985% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 93.717% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 64.609% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 102.686% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 97.521% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 103.202% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 100.27% |
| Verastem, Inc. | -37.27 Million USD | 97.261% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 88.747% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 98.031% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 93.254% |
| Histogen Inc. | -7.48 Million USD | 86.363% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 95.275% |
| Surrozen, Inc. | -32.66 Million USD | 96.874% |
| Organovo Holdings, Inc. | -1.5 Million USD | 32.25% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 75.711% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 105.385% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 139.029% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 124.567% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 87.818% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 97.65% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 92.996% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 99.678% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -41.401% |
| Apollomics, Inc. | -27.39 Million USD | 96.273% |
| Amarin Corporation plc | -191.04 Million USD | 99.466% |
| Mesoblast Limited | 55.96 Million USD | 101.824% |
| Turnstone Biologics Corp. | -14.58 Million USD | 92.999% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 95.963% |
| Synaptogenix, Inc. | -28.66 Million USD | 96.438% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -9.081% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 102.095% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -18.433% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 85.948% |
| Exelixis, Inc. | -73.05 Million USD | 98.602% |
| Better Therapeutics, Inc. | -860 Thousand USD | -18.721% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 95.748% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 99.577% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 238.71% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 86.273% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 181.419% |
| Gritstone bio, Inc. | 39.49 Million USD | 102.585% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 98.786% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 61.21% |
| Avid Bioservices, Inc. | 169.72 Million USD | 100.602% |
| Insmed Incorporated | 721.62 Million USD | 100.141% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 88.831% |
| MediWound Ltd. | -5.32 Million USD | 80.815% |
| OmniAb, Inc. | 9.2 Million USD | 111.094% |
| Alector, Inc. | -35.63 Million USD | 97.135% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 101.188% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 79.282% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 107.712% |
| Zai Lab Limited | -775 Million USD | 99.868% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 100.3% |
| Aura Biosciences, Inc. | -21.52 Million USD | 95.257% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 98.762% |
| Immunic, Inc. | -45.34 Million USD | 97.748% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 99.472% |
| Veracyte, Inc. | -203.82 Million USD | 99.499% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 100.16% |
| FibroGen, Inc. | 56.76 Million USD | 101.799% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 111.465% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 63.885% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 50.685% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.022% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 69.44% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 99.385% |
| TG Therapeutics, Inc. | 17.86 Million USD | 105.716% |
| Galecto, Inc. | -21.21 Million USD | 95.188% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 95.707% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 100.065% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 95.828% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 91.127% |
| XBiotech Inc. | -200.02 Million USD | 99.49% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 98.786% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 122.549% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 97.105% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 98.678% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 117.941% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 99.401% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 98.895% |
| Vaxxinity, Inc. | 10.13 Million USD | 110.077% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 100.139% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 90.518% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 98.452% |
| NexImmune, Inc. | -3.13 Million USD | 67.418% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 70.429% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 93.244% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 96.232% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 88.625% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -719.587% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 97.483% |
| Ainos, Inc. | 4.07 Million USD | 125.037% |
| Pluri Inc. | 22.82 Million USD | 104.472% |
| Prothena Corporation plc | -608.34 Million USD | 99.832% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 99.14% |
| Celularity Inc. | 65.19 Million USD | 101.566% |
| Rallybio Corporation | -24.1 Million USD | 95.764% |
| Cue Biopharma, Inc. | -33.81 Million USD | 96.981% |
| MeiraGTx Holdings plc | -40.3 Million USD | 97.467% |
| Omeros Corporation | 331.17 Million USD | 100.308% |
| Humacyte, Inc. | -22.48 Million USD | 95.459% |
| Immunocore Holdings plc | -358.59 Million USD | 99.715% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 95.845% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 96.696% |
| Blueprint Medicines Corporation | 702.83 Million USD | 100.145% |
| CalciMedica, Inc. | -5.53 Million USD | 81.537% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 99.458% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 90.004% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 97.45% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 96.93% |
| Pulmatrix, Inc. | -10.41 Million USD | 90.199% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 82.918% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 97.323% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 99.083% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 98.297% |
| Cytokinetics, Incorporated | 642.37 Million USD | 100.159% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 82.466% |
| Nutriband Inc. | -251.65 Thousand USD | -305.711% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 97.008% |
| Vor Biopharma Inc. | 4.3 Million USD | 123.744% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.983% |
| Evogene Ltd. | -19.63 Million USD | 94.8% |
| ProKidney Corp. | -56.23 Million USD | 98.184% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 97.902% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 88.947% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 100.075% |
| CorMedix Inc. | -43.05 Million USD | 97.628% |
| BioLineRx Ltd. | 7.33 Million USD | 113.918% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 96.283% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 102.212% |
| Atai Life Sciences N.V. | -28.55 Million USD | 96.425% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 145.774% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 95.525% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 105.757% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 98.64% |
| MediciNova, Inc. | -50.78 Million USD | 97.99% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 98.704% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -4438.786% |
| GeoVax Labs, Inc. | -6.45 Million USD | 84.177% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 99.489% |
| Biomea Fusion, Inc. | -166.57 Million USD | 99.387% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 99.43% |
| Mereo BioPharma Group plc | -51.46 Million USD | 98.016% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 98.923% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 99.652% |
| Absci Corporation | -72.59 Million USD | 98.594% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 122.361% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 99.564% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 98.916% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 98.933% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 97.387% |
| Allakos Inc. | -24.97 Million USD | 95.912% |
| Imunon, Inc. | -4.21 Million USD | 75.77% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 93.074% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 99.246% |
| BioAtla, Inc. | -109.01 Million USD | 99.063% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 238.71% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -8.733% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 108.533% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 95.185% |
| XOMA Corporation | -29 Million USD | 96.479% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 93.835% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 88.676% |
| aTyr Pharma, Inc. | -7.44 Million USD | 86.293% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 99.181% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 99.51% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 98.752% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 98.899% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -18.834% |
| Akari Therapeutics, Plc | -3.84 Million USD | 73.446% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 162.912% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.074% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 14.067% |
| UroGen Pharma Ltd. | 4.39 Million USD | 123.252% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 100.9% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 1518.804% |
| Orgenesis Inc. | 21.78 Million USD | 104.687% |
| Entera Bio Ltd. | -10.62 Million USD | 90.394% |
| GH Research PLC | -78.07 Million USD | 98.692% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 95.419% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 96.17% |
| Xencor, Inc. | 29.64 Million USD | 103.444% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 48.168% |
| Replimune Group, Inc. | 1.41 Million USD | 172.309% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -316.891% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 99.192% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 14.067% |
| Portage Biotech Inc. | -4.98 Million USD | 79.502% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -4438.786% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 98.456% |
| OncoCyte Corporation | -6.56 Million USD | 84.443% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 213.771% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 77.588% |
| Purple Biotech Ltd. | -14.13 Million USD | 92.778% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 95.702% |
| scPharmaceuticals Inc. | -6.54 Million USD | 84.4% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 93.883% |
| HilleVax, Inc. | -165.48 Million USD | 99.383% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 59.771% |
| Tharimmune, Inc. | -10.93 Million USD | 90.663% |
| Genprex, Inc. | -6.73 Million USD | 84.846% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 99.723% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 98.846% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 27.123% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 69.219% |
| OKYO Pharma Limited | -826.84 Thousand USD | -23.481% |
| Savara Inc. | 153 Thousand USD | 767.32% |
| Curis, Inc. | -23.88 Million USD | 95.726% |
| Daré Bioscience, Inc. | -5.15 Million USD | 80.205% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -31.57% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 83.553% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 186.16% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.955% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 108.275% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 99.832% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 99.45% |
| Erasca, Inc. | -37.21 Million USD | 97.257% |
| bluebird bio, Inc. | 108.57 Million USD | 100.94% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 20.723% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 100.27% |
| DBV Technologies S.A. | -126.98 Million USD | 99.196% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 20.723% |
| Moderna, Inc. | -2.9 Billion USD | 99.965% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 90.137% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 90.605% |
| Molecular Templates, Inc. | 707 Thousand USD | 244.413% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 96.745% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 100.295% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 98.756% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 98.887% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 96.836% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 97.03% |
| MacroGenics, Inc. | -66.98 Million USD | 98.476% |
| RenovoRx, Inc. | -1.17 Million USD | 12.958% |
| Adicet Bio, Inc. | -138.78 Million USD | 99.264% |
| Prime Medicine, Inc. | -27.94 Million USD | 96.346% |
| Aditxt, Inc. | 18.12 Million USD | 105.634% |
| Adagene Inc. | -87.62 Million USD | 98.835% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 75.489% |
| Quantum-Si incorporated | -118.55 Million USD | 99.139% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 102.836% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 86.34% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 97.895% |
| SciSparc Ltd. | -2.06 Million USD | 50.557% |
| Vericel Corporation | 1.27 Million USD | 179.953% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 91.486% |
| Minerva Neurosciences, Inc. | 41 Million USD | 102.49% |
| Generation Bio Co. | 31.44 Million USD | 103.247% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 99.418% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 96.698% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 100.876% |
| Invivyd, Inc. | -198.47 Million USD | 99.486% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 98.869% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 57.417% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 98.558% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 85.04% |
| 2seventy bio, Inc. | 181.71 Million USD | 100.562% |
| ADMA Biologics, Inc. | 90.06 Million USD | 101.134% |
| Clene Inc. | 3.34 Million USD | 130.569% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 88.759% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 95.254% |
| GeoVax Labs, Inc. | -6.45 Million USD | 84.177% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 99.703% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 96.073% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 100.575% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 75.046% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 120.412% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 80.399% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 99.216% |
| Evaxion Biotech A/S | 5.28 Million USD | 119.312% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 99.093% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 99.222% |
| Trevena, Inc. | 2.25 Million USD | 145.217% |
| Surrozen, Inc. | -32.66 Million USD | 96.874% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 98.018% |
| Cingulate Inc. | 3.08 Million USD | 133.12% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 65.237% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 114.206% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 89.011% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 98.713% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 99.223% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 99.033% |
| Clearmind Medicine Inc. | -3.94 Million USD | 74.104% |
| Kronos Bio, Inc. | -36.05 Million USD | 97.168% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 110.851% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 170.021% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 98.118% |
| Statera Biopharma, Inc. | 14.41 Million USD | 107.082% |
| ImmunityBio, Inc. | 618.22 Million USD | 100.165% |
| Korro Bio, Inc. | -132.94 Million USD | 99.232% |
| Kineta, Inc. | -4.54 Million USD | 77.516% |
| BioVie Inc. | -17.73 Million USD | 94.242% |
| Codexis, Inc. | -43.27 Million USD | 97.64% |
| Celularity Inc. | 65.19 Million USD | 101.566% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 67.782% |
| Celcuity Inc. | 6.78 Million USD | 115.051% |
| Virax Biolabs Group Limited | -3.36 Million USD | 69.658% |
| Cibus, Inc. | -8.07 Million USD | 87.361% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 75.857% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 122.341% |
| IN8bio, Inc. | -16.38 Million USD | 93.77% |
| Kodiak Sciences Inc. | -103.87 Million USD | 99.017% |
| Annexon, Inc. | -193.75 Million USD | 99.473% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 2936.111% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 94.165% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 70.937% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.097% |
| Eyenovia, Inc. | 1.25 Million USD | 181.115% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 103.795% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 68.517% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 96.929% |
| Arcellx, Inc. | -296.95 Million USD | 99.656% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 94.766% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 98.266% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 95.074% |
| Moolec Science SA | 117.61 Thousand USD | 968.079% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 97.341% |
| Geron Corporation | 14.76 Million USD | 106.917% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 97.307% |
| Royalty Pharma plc | 5.65 Billion USD | 100.018% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 99.278% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 85.392% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 80.962% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 99.275% |
| Humacyte, Inc. | -22.48 Million USD | 95.459% |
| Structure Therapeutics Inc. | -124.33 Million USD | 99.179% |
| 89bio, Inc. | -289.05 Million USD | 99.647% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 95.955% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 42.737% |
| Genelux Corporation | -6.89 Million USD | 85.201% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 96.713% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 101.221% |
| Notable Labs, Ltd. | -9.77 Million USD | 89.556% |
| Liquidia Corporation | -80.17 Million USD | 98.727% |
| Mustang Bio, Inc. | -3.73 Million USD | 72.671% |
| Immunovant, Inc. | -635.22 Million USD | 99.839% |
| Quantum-Si incorporated | -118.55 Million USD | 99.139% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 94.187% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 75.356% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 112.72% |
| Acasti Pharma Inc. | -23 Million USD | 95.562% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 69.678% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 93.717% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 99.259% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 67.237% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 95.408% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 94.502% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 99.397% |
| PepGen Inc. | -60.67 Million USD | 98.317% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 95.556% |
| United Therapeutics Corporation | -507.7 Million USD | 99.799% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 94.662% |
| Solid Biosciences Inc. | -47.75 Million USD | 97.862% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -18.433% |
| Immuneering Corporation | -54.94 Million USD | 98.142% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 75.711% |
| Silo Pharma, Inc. | -3.52 Million USD | 71.03% |
| Belite Bio, Inc | -87.27 Million USD | 98.83% |
| XOMA Corporation | -29 Million USD | 96.479% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 98.556% |
| Bionomics Limited | 227 Million USD | 100.45% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 99.122% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 59.692% |
| uniQure N.V. | -102.95 Million USD | 99.008% |
| Cassava Sciences, Inc. | -121.13 Million USD | 99.157% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 75.489% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 102.493% |
| Forte Biosciences, Inc. | -11.96 Million USD | 91.464% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 67.003% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 1063.208% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 68.517% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 111.465% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 86.232% |
| Altimmune, Inc. | -134.48 Million USD | 99.241% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 100.515% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 59.692% |
| Compugen Ltd. | -12.9 Million USD | 92.088% |
| Peak Bio, Inc. | 10.34 Million USD | 109.874% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -260.777% |
| Benitec Biopharma Inc. | -50.58 Million USD | 97.981% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 99.021% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 105.197% |
| Zura Bio Limited | -99.8 Million USD | 98.977% |
| PolyPid Ltd. | 6.17 Million USD | 116.548% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 101.377% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 105.197% |
| Instil Bio, Inc. | 75.35 Million USD | 101.355% |
| argenx SE | -2.02 Billion USD | 99.95% |
| Immunome, Inc. | -97.02 Million USD | 98.948% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 95.461% |
| Verona Pharma plc | -220.44 Million USD | 99.537% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 98.577% |
| Shattuck Labs, Inc. | -121.42 Million USD | 99.159% |
| CervoMed Inc. | -7.79 Million USD | 86.898% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 99.45% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 76.652% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 99.225% |
| Moolec Science SA | 117.61 Thousand USD | 968.079% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 55.375% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 106.422% |
| AnaptysBio, Inc. | -18.15 Million USD | 94.375% |
| Design Therapeutics, Inc. | -18.15 Million USD | 94.375% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 98.549% |
| NeurAxis, Inc. | 145.7 Thousand USD | 800.755% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 109.09% |
| Lumos Pharma, Inc. | -28.49 Million USD | 96.417% |
| Achilles Therapeutics plc | -126.92 Million USD | 99.196% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 98.577% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -55.704% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 95.085% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 170.021% |
| Nutriband Inc. | -251.65 Thousand USD | -305.711% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 92.248% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 86.277% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 100.3% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 104.302% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 99.772% |
| Palisade Bio, Inc. | -12.06 Million USD | 91.536% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 99.272% |
| Beam Therapeutics Inc. | -262.72 Million USD | 99.611% |
| Neurogene Inc. | -131.95 Million USD | 99.226% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 104.68% |
| AEON Biopharma, Inc. | -4.88 Million USD | 79.078% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 99.729% |
| Sesen Bio, Inc. | -112.55 Million USD | 99.093% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 98.978% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 56.512% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 97.384% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 98.774% |
| Athira Pharma, Inc. | -88.99 Million USD | 98.853% |
| Vaccinex, Inc. | -1.28 Million USD | 20.73% |
| HCW Biologics Inc. | 2.85 Million USD | 135.741% |
| XOMA Corporation | -29 Million USD | 96.479% |
| Nektar Therapeutics | 210.24 Million USD | 100.486% |
| Arvinas, Inc. | -313.8 Million USD | 99.675% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 162.912% |
| Merus N.V. | -192.88 Million USD | 99.471% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 101.702% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 85.284% |
| Rezolute, Inc. | -68.16 Million USD | 98.502% |
| Clene Inc. | 3.34 Million USD | 130.569% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 92.258% |
| BeyondSpring Inc. | -13.75 Million USD | 92.577% |
| Synlogic, Inc. | -6.68 Million USD | 84.727% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 190.035% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 87.924% |
| Peak Bio, Inc. | 10.34 Million USD | 109.874% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 98.761% |
| Krystal Biotech, Inc. | -350.23 Million USD | 99.708% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 100.823% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 99.396% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 67.661% |
| MannKind Corporation | 143.89 Million USD | 100.71% |
| Ikena Oncology, Inc. | -109.15 Million USD | 99.065% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 86.514% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 96.915% |
| Gossamer Bio, Inc. | 180.35 Million USD | 100.566% |
| CohBar, Inc. | -5.93 Million USD | 82.785% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 96.568% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 122.361% |
| Legend Biotech Corporation | -949.39 Million USD | 99.892% |
| Mural Oncology plc | -255.84 Million USD | 99.601% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 103.169% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 78.326% |
| Disc Medicine, Inc. | -358.28 Million USD | 99.715% |
| Champions Oncology, Inc. | 4.81 Million USD | 121.218% |
| REGENXBIO Inc. | 54.76 Million USD | 101.864% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -279.685% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 99.324% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 88.671% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 98.735% |
| Vaxart, Inc. | -8.24 Million USD | 87.611% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 97.965% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 99.197% |
| Cellectis S.A. | -43.85 Million USD | 97.672% |
| Longeveron Inc. | -2.9 Million USD | 64.89% |
| Repare Therapeutics Inc. | -107.85 Million USD | 99.053% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.105% |
| Inozyme Pharma, Inc. | 12 Million USD | 108.505% |
| Revolution Medicines, Inc. | -608.2 Million USD | 99.832% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 16.992% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 99.615% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 99.32% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 93.475% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -37.973% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.989% |
| Denali Therapeutics Inc. | -74.86 Million USD | 98.636% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 91.486% |
| Veru Inc. | 4.77 Million USD | 121.36% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 90.921% |
| Cingulate Inc. | 3.08 Million USD | 133.12% |
| Passage Bio, Inc. | 4.58 Million USD | 122.268% |
| Context Therapeutics Inc. | -14.44 Million USD | 92.934% |
| Exicure, Inc. | 5.84 Million USD | 117.456% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 99.557% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 97.42% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 106.507% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 98.264% |
| Nuvalent, Inc. | -335.38 Million USD | 99.696% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 158.87% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 98.629% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 88.515% |
| OmniAb, Inc. | 9.2 Million USD | 111.094% |
| Anew Medical, Inc. | 1.43 Million USD | 171.276% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 106.233% |
| Lipocine Inc. | -4.75 Million USD | 78.526% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 99.07% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 106.703% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 97.985% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 104.102% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 84.809% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 98.449% |
| Ocugen, Inc. | -32.52 Million USD | 96.86% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 98.807% |
| Q32 Bio Inc. | -37.94 Million USD | 97.309% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -62.58% |
| Alumis Inc. Common Stock | -13.52 Million USD | 92.453% |
| Equillium, Inc. | -22.39 Million USD | 95.44% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 96.007% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 96.871% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -311.835% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 100.762% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 131.926% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 410.863% |
| Dominari Holdings Inc. | 195 Thousand USD | 623.59% |
| Edesa Biotech, Inc. | -5.26 Million USD | 80.615% |
| vTv Therapeutics Inc. | -8.91 Million USD | 88.55% |
| Bio-Techne Corporation | 267.74 Million USD | 100.381% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 93.701% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 99.135% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 87.85% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 91.929% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 99.583% |
| Nkarta, Inc. | 57.29 Million USD | 101.782% |
| BioCardia, Inc. | 212 Thousand USD | 581.604% |
| Iterum Therapeutics plc | 13.43 Million USD | 107.598% |